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ABSTRACT 
Objective: The primary objective of the current research was to prepare rilpivirine loaded Nanoparticles containing Chitosan using the ionic 
gelation method for HIV infections.  
Methods: The nanoparticles of rilpivirine were prepared using the ionic gelation technique. Further, nanoparticles were characterized by Fourier 
transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), scanning electron microscopy (SEM) and in vitro drug release.  
Results: The optimized nanoparticles were found with a particle size of 130.30±5.29 nm (mean±SD) and entrapment efficiency (% EE) of 
77.10±0.50%. Scanning electron microscopy technique exposed spherical particles with uniform size. It was observed that the nanoparticles created 
showed the absence of the crystalline nature of the drug and its switch to the amorphous state. Results showed that more than 45% of the pure drug 
is released in 50 min and after 90 min almost about 95% of the drug is released.  
Conclusion: The research study concluded that the in vitro release profile of nanoparticles was found to be sustained up to 24 hr. Sustained release 
of the rilpivirine could improve patient obedience to drug regimens, growing action effectiveness.  
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INTRODUCTION 
Chitosan is an interesting natural material occurring in abundance in 
the environment. Its excellent biocompatibility and several 
advantages due to its unique polymer cationic character render it 
highly useful for pharmaceutical applications. A polysaccharide 
comparable to cellulose, comprising copolymers of glucosamine and 
N-acetyl glucosamine linked by β-(1–4) linkages, chitosan can be 
derived by partial deacetylation of chitin from crustacean shells. The 
primary amino groups lead to special properties that render 
chitosan very interesting for pharmaceutical applications. In 
contrast to most other natural polymers, it has a positive charge and 
is mucoadhesive. Besides other applications, chitosan has been 
extensively examined for its potential in the development of 
controlled release drug delivery systems and these controlled 
release formulations have been made in the form of chitosan gels, 
tablets, and capsules, in addition to microspheres and microcapsules 
[1-3]. 
Nanoparticles have a special role in targeted drug delivery in the 
sense that they have all the advantages of liposomes including the 
particle size, but unlike liposomes, nanoparticles have a long shelf 
life and can usually entrap more drugs than liposomes. Although 
nanoparticles made of hydrophobic polymers encapsulating 
hydrophobic drugs have been reported in the literature, very few 
studies have been made in the preparation of drug-loaded hydrogel 
nanoparticles. Nanoparticles made of hydrophobic polymers are 
usually taken up by the Reticuloendothelial system (RES) and have a 
short residence time in blood. The surfaces of these hydrophobic 
nanoparticles are made hydrophilic by conjugating with the 
polyethylene glycol (PEG) type of molecules to make these particles 
long circulating in blood [4, 5]. We have recently optimized a 
method of preparation of ultra-low size nanoparticles of hydrogel 
polymers and have been able to load water-soluble drugs into them. 
These hydrophilic nanoparticles evade RES and remain in 
circulation for a couple of hours without PEG conjugation on the 
particle surface [6]. These hydrogel polymers can have reactive 
groups on the surface which enable the nanoparticles to be 
converted to stimuli-responsive particles and they can also be made 
targetable by attaching receptor-specific ligands. The preparation of 
nanoparticles from chitosan, a hydrogel polymer, for drug delivery 
can have several advantages over the use of chitosan microspheres 
and microcapsules [7, 8].  
Nanometer range particles have easy accessibility in the body, being 
transported via the circulation to different body sites. Extremely 
small nanoparticles, of<100 nm diameter with a hydrophilic surface, 
have been found to have longer circulation in blood. Such systems 
should allow the control of the rate of drug administration that 
prolongs the duration of the therapeutic effect, as well as the 
targeting of the drug to specific sites [9]. The preparation of 
nanoparticles with this versatile hydrogel material has been 
attempted by several workers to utilize its mucoadhesive properties 
to transport drugs and DNA across a mucosal surface. The 
polycationic nature of deacetylated chitosan results in 
polycondensation in the presence of anionic macromolecules [10, 
11]. Thus, Chitosan–DNA nanoparticles can be prepared by the 
method of coacervation. Besides, the reactive free amino group on 
the particle surface makes it possible to chemically conjugate 
various other reactive groups, such as polyethylene glycol (PEG) 
derivatives, different ligands, antibodies, and other pH and 
temperature-sensitive moieties. Several methodologies have also 
incorporated other polymers in the preparative procedure, with the 
intent of preparing smart hydrophilic nanoparticles under extremely 
mild conditions [12-14].  
Considering the advantages of using ultra-low sized hydrophilic 
nanoparticles for drug delivery, we have focused on the preparation 
of chitosan nanoparticles of<100 nm diameter. The preparation of 
nanoparticles using reverse micelles as a medium makes it possible 
to produce ultrafine particles with narrow size distribution. The 
aqueous core of the reverse micellar droplets can be used as a 
nanoreactor to prepare these particles since the size of the reverse 
micellar droplets is in the nanometer range and these droplets are 
highly monodispersed. The present paper describes the preparation 
of cross-linked chitosan nanoparticles of size<100 nm diameter 
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using reverse micelles as the media and their physicochemical 
characterization as well as biodistribution.  
MATERIALS AND METHODS 
Materials 
Rilpivirine was obtained as a gift from Sun Pharma Advanced 
Research Center (SPARC), Vadodara, Guj. India. Chitosan was gifted 
from the Central Institute of Fisheries Technology, Cochin. All the 
other ingredients and solvents used in the preparation of 
nanoparticles were used as obtained and are of analytical grade. 
Preparation of rilpivirine loaded chitosan nanoparticles 
Rilpivirine loaded chitosan nanoparticles were prepared [15, 16]. 
with some modifications based on the ionic gelation of rilpivirine 
with tripolyphosphate (TPP) anions. Chitosan was dissolved in the 
1% acetic aqueous solution and rilpivirine was dissolved in 2% 
tween-80 solutions, which was added to the chitosan solution. 
Under mechanical stirring (1000 rpm) (Remi, India) at room 
temperature, 0.25 % sodium tripolyphosphate aqueous solution 
was added dropwise into drug and polymeric mixture for 30 min. 
Thereafter, the rilpivirine loaded chitosan particle suspension was 
processed under ultra-sonication by probe sonicator for 10 min, 
producing nanoparticles with controlled particle sizes. The 
dispersion was stored in a refrigerator until further evaluation. 
The arrangement of the nanoparticle was a result of the interface 
between the negative groups of the TPP and the positively charged 
amino groups of chitosan (ionic gelation). The formulation 
composition for chitosan loaded nanoparticles was depicted in 
table 1. 
 
Table 1: Formulation consideration of chitosan nanoparticles 
Batch code Rilpivirine (mg) 0.25 % TPP solution (ml) Rilpivirine (mg): chitosan 0.1 % w/v (ml) 
MJ-1 25 10 1:1 
MJ-2 25 10 1:2 
MJ-3 25 10 1:3 
MJ-4 25 10 1:4 
MJ-5 25 10 1:5 
MJ-6 25 10 1:6 
 
Preliminary investigation of formulation for nanoparticles  
Optimization of the nanoparticles was carried out using a varying 
amount of 1% chitosan and 0.25% TPP solution. Two different 
amounts of 1% chitosan i.e. 15 and 20 ml and three different amounts 
of 0.25% TPP viz. 6, 8, and 10 ml were used to screen the best batch-
based in the particle size and entrapment efficiency of nanoparticles. 
The batches were coded from M-1 to M-6 as shown in table 2. 
 
Table 2: Optimization parameters 
Batch Chitosan 0.1 % w/v (ml) 0.25 % TPP solution(ml) 
M-1 15 10 
M-2 15 08 
M-3 15 06 
M-4 20 10 
M-5 20 08 
M-6 20 06 
The rilpivirine loaded chitosan nanoparticles were prepared in six batches keeping the drug and 0.25% TPP constant at 25 mg and 10 ml 
respectively. The ratio for the drug (rilpivirine): chitosan was changed from 1:1 to 1:6 and coded as MJ-1 to MJ-6. Composition parameters are 
shown in table 1. 
 
Characterization of nanoparticles 
Determination of entrapment efficiency (%) 
Entrapment efficiency gives an idea about the %drug that is 
successfully entrapped/adsorbed into nanoparticles. Rilpivirine in the 
nanoparticles was analyzed by dissolving the nanoparticles in 0.5% 
Polysorbate-20 in 0.01 N HCl (pH 1.2). The concentration of 
nanoparticles in 0.5% polysorbate-20 in 0.01 N HCl was 10 mg/ml. 
The mixture was stirred continuously overnight at room temperature. 
Solutions were then analyzed by UV-Vis spectrophotometer at 304 nm 
with suitable dilutions [17]. The encapsulation efficiency was 




 × 100 
Where, TDC = total drug content, Df
Surface morphology 
 = free drug 
Scanning electron microscopy (SEM) is a method for high-resolution 
imaging of surfaces. The SEM uses electrons for imaging, much as a 
light microscope uses visible light. The advantages of SEM over light 
microscopy include much higher magnification (>100,000X) and 
greater depth of field up to 100 times that of light microscopy. 
Qualitative and quantitative chemical analysis information is also 
obtained using an energy dispersive x-ray spectrometer (EDS) with 
the SEM [18]. The SEM generates a beam of incident electrons in an 
electron column above the sample chamber. The electrons are 
produced by a thermal emission source, such as a heated tungsten 
filament, or by a field emission cathode. The energy of the incident 
electrons can be as low as 100 eV or as high as 30 keV depending on 
the evaluation objectives. The electrons are focused into a small beam 
by a series of electromagnetic lenses in the SEM column. Scanning coils 
near the end of the column direct and position the focused beam onto 
the sample surface. The electron beam is scanned in a raster pattern 
over the surface for imaging. The beam can also be focused at a single 
point or scanned along a line for x-ray analysis. The beam can be 
focused to a final probe diameter as small as about 10 Å [19]. To create 
an SEM image, the incident electron beam is scanned in a raster 
pattern across the sample's surface. The emitted electrons are 
detected for each position in the scanned area by an electron detector. 
The intensity of the emitted electron signal is displayed as brightness 
on a display monitor and/or in a digital image file. By synchronizing 
the position in the image scan to that of the scan of the incident 
electron beam, the display represents the morphology of the sample 
surface area. To examine the surface morphology of the nanoparticles 
samples were analyzed by SEM (JSM-6510LV, MA, USA). SEM analysis 
was performed at 1 kV with magnifications ranging from 4000× to 
12000×. SEM images were used to analyze the interface between the 
drug and the polymer [20, 21]. 
Patel et al. 
Int J Pharm Pharm Sci, Vol 12, Issue 2, 113-118 
115 
Particle size distribution study  
Particle size can be determined by measuring the random changes in 
the intensity of light scattered from a suspension or solution. This 
technique is commonly known as dynamic light scattering (DLS) but is 
also called photon correlation spectroscopy (PCS) and quasi-elastic 
light scattering (QELS). The latter terms are more common in older 
literature. DLS is most commonly used to analyze nanoparticles [22, 
23]. Dynamic light scattering (DLS) is based on the Brownian motion 
of dispersed particles. When particles are dispersed in a liquid they 
move randomly in all directions. The principle of Brownian motion is 
that particles are constantly colliding with solvent molecules. These 
collisions cause a certain amount of energy to be transferred, which 
induces particle movement. Laser diffraction particle size analyzer 
(Zetasizer Nano S90, Malvern, UK) was used for the determination of 
the particle size as well as the particle size distribution of the 
nanoparticles. The Zetasizer uses the dynamic light scattering (DLS) 
principle to determine the particle size, and measurements were made 
using a detection angle of 90 ° [24]. 
Fourier transform infrared spectroscopy (FTIR) 
Fourier Transform Infrared Spectroscopy spectra of HES, HP-b-CD 
and their prepared nanoparticles were taken in the range of 4000 to 
500 cm-1 (Mid-infrared region) on a Perkin Elmer device, equipped 
with ATR device (Shimadzu 8400S FTIR spectrometer, Japan) using 
Attenuated Total Reflectance (ATR) method. Smoothing of the 
spectra and baseline correction was applied [25]. 
Differential scanning calorimetry (DSC) 
DSC determinations were carried out in a stream of nitrogen 
atmosphere on a DSC 60A differential scanning calorimeter 
(Shimadzu, Japan). The accurately weighed sample (10 mg) was 
heated in hard-pressed plus perforated crucibles of aluminum, at a 
scanning rate of 10 °C min-1 and the 50 ml min-1
Dissolution testing is a requirement for all solid oral dosage forms 
and is used in all phases of development for product release and 
stability testing. It is a key analytical test used for detecting physical 
changes in an active pharmaceutical ingredient (API) and the 
formulated product. At the early stages of development, in vitro 
dissolution testing guides the optimization of drug release from 
formulations [28-31]. The dissolution studies for rilpivirine and its 
prepared nanoparticles were performed using a USP paddle 
apparatus. To mimic the conditions from the human gastrointestinal 
tract, the dissolution tests were carried out in a simulated medium 
[0.5% Polysorbate 20 in 0.01 N HCl (pH = 1.2)]. The agitating speed 
was set at 100 rpm and the temperature was kept at 37±0.5 °C. 
Samples were withdrawn at a time interval of every 1 hr up to 24 h. 
Aliquots of 5 ml were withdrawn from the apparatus and the same 
quantity of fresh dissolution medium was replaced at each sampling 
time. The solutions were immediately filtered through a 0.45 mm 
membrane filter, suitably diluted and the concentration of rilpivirine 
was measured by UV spectrophotometer at 304 nm against a blank 
containing the fresh dissolution medium. Suitable constructed 
standard curves were used. All dissolution measurements were 
performed in triplicate. The dissolution study plots were 
constructed by plotting the mean values of the cumulative 
dissolution of rilpivirine vs. time. 
flow rate of nitrogen. 
Consistent with standard procedures, the machine was calibrated 
for temperature as well as sensitivity with indium [26, 27]. 
In vitro dissolution studies 
RESULTS 
Solubility study 
The solubility of rilpivirine in deionized water and dissolution 
medium. The solubility of rilpivirine in water and dissolution 
medium at 37 °C±1 °C was found to be 3.93 mg/ml and 3.63 
mg/ml respectively. The solubility data of drugs in the 
dissolution medium confirm the presence of sink conditions in 
the media. 
Preliminary investigation in the formulation of nanoparticles 
Results of preliminary batches prepared for nanoparticle 
formulation was indicated in table 3. Preliminary batches were 
prepared to understand the effects of chitosan and TPP over the 
particle size and entrapment efficiency when used together. The 
preliminary batches were analyzed and the amount of 0.25 % TPP 
was finalized to be 10 ml for further studies. 
Characterization of formulation 
Particle size and PDI 
The nanoparticles prepared were analyzed for their size and 
relevant PDI was determined with the help of Malvern Zetasizer 
Nano ZS-90. The codes denote the ratio of drug to chitosan solution 
in the ascending order from 1:1 to 1:6. The particle sizes of the 
nanoparticles were from 130.30±5.29 to 350.80±13.17 nm. The 
results were shown in table 4. 
  
Table 3: Optimization of development parameters 
Batch Chitosan 0.1 % w/v (ml) 0.25 % TPP solution (ml) Particle size (nm) % Entrapment efficiency* * 
M-1 15 10 560±12.02 70.12±4.02 
M-2 15 08 720±14.45 62.45±3.12 
M-3 15 06 840±11.30 59.32±5.32 
M-4 20 10 785±10.85 65.78±6.82 
M-5 20 08 876±12.28 62.45±2.98 
M-6 20 06 942±15.40 59.32±6.36 
*
 
 Values of particle size and % Entrapment efficiency was presented as mean±SD (n=3) 
Table 4: Particle size distribution data for rilpivirine loaded chitosan nanoparticles 
Batch code Particle size (nm) PDI* * 
MJ-1 154.90±4.40 0.82±0.06 
MJ-2 130.30±5.29 0.98±0.11 
MJ-3 141.30±8.81 0.73±0.06 
MJ-4 207.60±6.60 0.81±0.02 
MJ-5 190.32±6.60 0.77±0.12 
MJ-6 350.80±13.17 0.66±0.04 
*
 
Zeta potential  
Values of particle size and PDI were presented as mean±SD (n=3). 
Zeta potential was determined by Zetasizer (Malvern Instruments, 
Malvern, UK) using a disposable potential cuvette. For the selected 
batch MJ-2 sample, the mean zeta potential was found to be 
25.38±2.18 mV and polydispersity of all formulation was closer to 1. 
The results of the zeta potential were presented in table 5. 
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Table 5: Zeta potential of rilpivirine loaded chitosan nanoparticles 









Scanning electron microscopy (SEM) 
Morphological characteristics of rilpivirine loaded Chitosan 
nanoparticle were analyzed by Scanning electron microscopy (SEM). 
Fig. 1 displayed SEM images for rilpivirine loaded chitosan 
nanoparticles.  
Entrapment efficiency 
Values of zeta potential was presented as mean±SD (n=3). 
Entrapment efficiency was calculated to determine the amount of 
rilpivirine entrapped inside the nanoparticle or been adsorbed on its 
surface. 10 mg of nanoparticles were suspended in 10 ml 
polysorbate-20 in 0.01 N HCl (pH 1.2) to extract the drug from 
nanoparticles. The mixture was stirred vigorously and been kept 
overnight at room temperature. The solution was then centrifuged 
and the supernatant was collected carefully using a micropipette. 
Solutions were then analyzed by a UV-Vis spectrophotometer at 304 
nm with suitable dilutions. The data of drug entrapment efficiency of 
drug-loaded nanoparticles were as shown in table 6 the % 
encapsulation efficiencies of the nanoparticles were found in the 
range from 65.85±0.45 to 78.40±0.10. 
 
 
Fig. 1: SEM photographs for rilpivirine loaded chitosan nanoparticles MJ-2 
 
Table 6: Entrapment efficiency of rilpivirine loaded chitosan nanoparticles 









Values of % Entrapment efficiency was presented as mean±SD (n=3). 
 
Fig. 2: DSC thermogram of rilpivirine, chitosan, and nanoparticles 
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Fig. 3: FTIR spectra of rilpivirine, chitosan, and nanoparticles 
 
 
Fig. 4: Dissolution profile of rilpivirine and rilpivirine loaded chitosan nanoparticles 
 
DSC thermogram  
The DSC thermogram was utilized to study the changes over the 
structure of the drug and chitosan. The DSC thermogram of rilpivirine 
(fig. 2) showed an endothermic Tmax of 249 °C, corresponding to the 
melting point of the crystalline form of rilpivirine. Rilpivirine melts 
with decomposition which starts at about 249 °C. The DSC 
thermogram of chitosan shows an endothermic Tmax
FTIR spectra 
 of 78 °C. 
Fig. 3 illustrated the FTIR spectra of rilpivirine, chitosan, and 
nanoparticles. The IR spectrum of rilpivirine is characterized by 
typical absorption bands at about 2217 cm-1 (C-N), 1652 cm-1 (C-O 
stretch) and 1497 cm-1
In vitro drug release study 
 (aromatic C-C). 
The dissolution curves of rilpivirine and nanoparticles in 0.5% 
Polysorbate 20 in 0.01 N HCl (pH=1.2) at 37±0.5 °C are shown in fig. 
4. It was observed that more than 45% of the pure rilpivirine was 
released in 50 min. After 90 min almost about 95% and after 120 
min complete rilpivirine was released. While the in vitro release 
profile of nanoparticles was found to be sustained up to 24 h. 
DISCUSSION 
Preliminary batches of the rilpivirine nanoparticles were prepared 
to finalize the concentration of TPP. It was observed that with the 
increase in the amount of 0.1% chitosan volume, irregular particle 
formation was observed. It also increased the particle size and 
decreased the entrapment efficiency, with every increase in the 
chitosan amount. Hence, 10 ml 0.25% TPP with 15 ml of 0.1% 
chitosan was finalized for the preparation of nanoparticles as it 
showed lower particle size and higher entrapment efficiency. The 
results of particle size distribution study indicated an irregular 
pattern in the particle size distribution, but a bigger picture of the 
increase in the particle size is observed with an increase in the 
chitosan amount [1, 3, 5]. Batch MJ-2 was found to be having the 
least particle size and based on that it was selected as the optimized 
batch. Nanoparticles formulation shows a narrow size distribution 
with a lower standard deviation. Zeta potential and polydispersity 
index showed that all particles in the formulation were in the 
acceptable range, inferring to be a stable formulation. The 
magnitude of the zeta potential is predictive of colloidal stability. 
Nanoparticles with zeta potential values greater than+25 mV typically 
have high degrees of stability [30, 31]. The SEM images (fig. 1) 
revealed that the nanoparticles were spherical and no 
agglomeration was observed indicating its stability. SEM images of 
obviously indicated the interface of drug with a polymeric material 
and accomplished the amalgamation of the drug in matrix material 
[11]. In the DSC thermograms of nanoparticles the sharp melting 
point peak of pure rilpivirine at 249 °C and was not noticeable. The 
characteristic features of the rilpivirine peak were lost in the 
nanoparticles [14]. This phenomenon indicates that rilpivirine was 
molecularly detached and was no longer present there as a 
crystalline material, but was changed into the amorphous state. It 
also reveals that there was no free rilpivirine other than those 
entrapped in the nanoparticles confirming over its entrapment and 
stability [18]. In the results of FTIR spectra, there was a decrease of 
peak intensities is experiential in nanoparticles representative 
physically powerful physical interaction of the drug with carrier 
materials. However, no additional peaks were observed in any of the 
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binary systems, indicating the absence of any chemical interface 
among rilpivirine and the chitosan [20]. The in vitro dissolution 
study for nanoparticles indicated that it sustains the drug release 
(fig. 4), for MJ-1 release up to 20 h was observed, whereas for MJ-2 it 
increased to 24 hr. For MJ-3 and MJ-4, the complete release was 
observed after 20 h and for MJ-5 and MJ-6, it was observed after 16 
h. The data suggests that there is no direct relationship between 
increasing the chitosan solution in the nanoparticle with sustained 
release. As they show a decreased release profile with an increase in 
the ratio, there should be coordination between the particle size and 
the release profile. It was observed that with an increase in the 
particle size there was a decreased period in their successful 
complete release. The release pattern was found to be similar in all 
the batches of nanoparticles formulated [21]. 
CONCLUSION 
In conclusion, the present study focused on the preparation of 
rilpivirine loaded nanoparticles containing Chitosan using the ionic 
gelation method for HIV infections. Nanoparticles were 
characterized by Fourier transform infrared spectroscopy (FTIR), 
differential scanning calorimetry (DSC), scanning electron 
microscopy (SEM) and in vitro drug release. The optimized 
nanoparticles were found with a particle size of 130.30±5.29 nm. 
The entrapment efficiency (% EE) of the chitosan nanoparticles 
were found to be 77.10±0.50%. Morphological structures were 
studied using scanning electron microscopy which exposed the 
particles to be spherical with uniform size. It was observed that the 
nanoparticles formulated showed the absence of the crystalline 
nature of the drug and its switch to the amorphous state, which was 
confirmed through SEM and FTIR. Results showed that more than 
45% of the pure drug was released in 50 min and after 90 min 
almost about 95% of the drug is released. While the in vitro release 
profile of chitosan nanoparticles was found to be sustained up to 24 
hr. Sustained release of the rilpivirine could improve patient 
obedience to drug regimens, growing action effectiveness. Stability 
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